A Nonsteroidal Novel Formulation Targeting Inflammatory and Pruritus-Related Mediators Modulates Experimental Allergic Contact Dermatitis
| Autor: | Nicolas G. Bazan, Bokkyoo Jun, David Rodríguez Gil, Gabriela Silvina Bacchini, William C. Gordon, Fernando Pineda De La Losa, Ricardo Palacios Pelaez, Hélène Varoqui, Virginia García López, Javier Alcover Díaz, Surjyadipta Bhattacharjee, Concha Tiana Ferrer |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Experimental allergic Croton lechleri Inflammation Dermatology Pharmacology Nonsteroidal therapy 03 medical and health sciences chemistry.chemical_compound Dinitrofluorobenzene Disodium cromoglycate medicine Allergic contact dermatitis Original Research Cromoglycate Nonsteroidal biology business.industry medicine.disease biology.organism_classification 3. Good health 030104 developmental biology chemistry Ear thickness Experimental allergic contact dermatitis medicine.symptom business Contact dermatitis |
| Zdroj: | Dermatology and Therapy |
| ISSN: | 2193-8210 |
| Popis: | Introduction A major clinical challenge in treating allergic contact dermatitis (ACD) is that the first line of treatment is based on the use of corticosteroids. In this study, we aimed to develop a formulation that is devoid of steroids. Methods We used mouse ears treated with dinitrofluorobenzene (DNFB) to induce ACD. The efficacy of the test formulation to ameliorate and to prevent induced ACD was determined. Results To treat this experimentally induced ACD, we developed a formulation containing BIPxine (a mixture of Rosa moschata and Croton lechleri (antioxidants) and Aloe vera and d-panthenol (moisturizers), and hydroglycolic solutions of disodium cromoglycate. Our results show that clear inhibition of ACD took place. The target of this formulation was PAR-2, TRPV4, and other mediators of the inflammatory and pain responses. However, this formulation must be evaluated in other models besides the mouse to confirm its effectiveness. Conclusion The formulation presented here may provide new ACD therapies that do not involve the use of corticosteroids. Electronic supplementary material The online version of this article (10.1007/s13555-018-0223-8) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink